Biomind Labs Stock Performance
| BMNDF Stock | USD 0.11 0.02 22.77% |
Biomind Labs holds a performance score of 10 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 3.87, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Biomind Labs will likely underperform. Use Biomind Labs total risk alpha, as well as the relationship between the daily balance of power and day typical price , to analyze future returns on Biomind Labs.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Biomind Labs are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile fundamental indicators, Biomind Labs reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Biomind |
Biomind Labs Relative Risk vs. Return Landscape
If you would invest 1.58 in Biomind Labs on September 26, 2025 and sell it today you would earn a total of 9.42 from holding Biomind Labs or generate 596.2% return on investment over 90 days. Biomind Labs is currently producing 7.3474% returns and takes up 55.4012% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Biomind, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Biomind Labs Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biomind Labs' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Biomind Labs, and traders can use it to determine the average amount a Biomind Labs' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1326
| Best Portfolio | Best Equity | BMNDF | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Biomind Labs is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biomind Labs by adding it to a well-diversified portfolio.
Biomind Labs Fundamentals Growth
Biomind Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Biomind Labs, and Biomind Labs fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biomind Pink Sheet performance.
| Return On Equity | -5.72 | |||
| Return On Asset | -2.59 | |||
| Current Valuation | 39.1 M | |||
| Shares Outstanding | 74.76 M | |||
| Price To Book | 143.15 X | |||
| EBITDA | (4.3 M) | |||
| Cash And Equivalents | 1.61 M | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 39.44 K | |||
| Debt To Equity | 0.02 % | |||
| Book Value Per Share | 0.02 X | |||
| Cash Flow From Operations | (2.12 M) | |||
| Earnings Per Share | (0.07) X | |||
| Total Asset | 2.53 M | |||
About Biomind Labs Performance
By analyzing Biomind Labs' fundamental ratios, stakeholders can gain valuable insights into Biomind Labs' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Biomind Labs has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Biomind Labs has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. It is also developing new and preclinical drug candidates, including BMND02 for treating fibromyalgia, BMND03 for treating addictive disorders, BMND05 for treating chronic pain, BMND06 for treating inflammation, and BMND07 for treating major depressive disorder. Biomind Labs is traded on OTC Exchange in the United States.Things to note about Biomind Labs performance evaluation
Checking the ongoing alerts about Biomind Labs for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Biomind Labs help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Biomind Labs is way too risky over 90 days horizon | |
| Biomind Labs has some characteristics of a very speculative penny stock | |
| Biomind Labs appears to be risky and price may revert if volatility continues | |
| Biomind Labs has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (4.33 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Biomind Labs has accumulated about 1.61 M in cash with (2.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. | |
| Roughly 90.0% of the company shares are held by company insiders |
- Analyzing Biomind Labs' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biomind Labs' stock is overvalued or undervalued compared to its peers.
- Examining Biomind Labs' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biomind Labs' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biomind Labs' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Biomind Labs' pink sheet. These opinions can provide insight into Biomind Labs' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Biomind Pink Sheet analysis
When running Biomind Labs' price analysis, check to measure Biomind Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomind Labs is operating at the current time. Most of Biomind Labs' value examination focuses on studying past and present price action to predict the probability of Biomind Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomind Labs' price. Additionally, you may evaluate how the addition of Biomind Labs to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |